Okinawa in Japan finds contaminants in Moderna Covid-19 vaccines: Report

Contaminants were found in Moderna Inc’s Covid-19 vaccines at a large-scale vaccination centre in Japan’s Okinawa prefecture, suspending inoculations, public broadcaster NHK reported on Sunday.

The Okinawa vaccines are from different Moderna lots already suspended by the Japanese government due to reports of contamination, NHK said.

Black substances were spotted in syringes and a vial, while pink substances were found in a different syringe filled with vaccine at the Okinawa centre, NHK said.

Takeda Pharmaceutical Co, the domestic distributor of the Moderna vaccines, is expected to investigate the possibility of contamination during production and hold talks with Japan’s health ministry, the broadcaster said.

Japan halted the use of 1.63 million Moderna doses, shipped to 863 vaccination centres nationwide, more than a week after Takeda received reports of contaminants in some vials.

The ministry said on Saturday that two people died after receiving Moderna’s vaccine shots that were among lots later suspended following the discovery of contaminants.

Each had a shot from one of three manufacturing lots suspended on Thursday. The causes of death are being investigated.

Japan is battling its worst wave of infections, driven by the Delta variant, with new daily infections exceeding 25,000 this month for the first time.

The country has inoculated 54% of its population with at least one dose and fully vaccinated 43%, according to a Reuters vaccine tracker.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor